
The link between diabetes and late-stage breast cancer is strong, according to a new study.

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC), according to findings from an ongoing phase I study presented at the 2015 AACR Annual Meeting.

The link between diabetes and late-stage breast cancer is strong, according to a new study.

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the challenges of understanding the link between obesity and cancer.

Pierre Adams shares her story on being diagnosed while being pregnant with twins

In 2009, Connecticut became the first state to enact legislation mandating that patients undergoing mammography be informed of their breast density and the option to have a follow-up ultrasound.

Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.

In this roundtable, representatives from Sharsheret, the Cancer Support Community, the Young Survival Coalition, and Living Beyond Breast Cancer discuss the impact of metastatic breast cancer.

A new study has found that African American patients with cancer feel and describe depression differently than their Caucasian counterparts.

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, gives advice to nurses on how to manage pain in breast cancer patients.

A new study hopes to gain some clarity on what causes some breast cancer patients to feel "foggy" when receiving chemotherapy.

According to a recent retrospective cohort analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than do the general population, particularly if they receive adjuvant radiation therapy.

Having a family history of prostate cancer among first-degree relatives may also increase a women's risk of developing breast cancer, according to a new study.

Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the link between obesity and cancer.

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses tamoxifen as breast cancer prevention

With a career as remarkable and distinguished as Joan Lunden's, it's really no surprise that she took on her latest challenge-a diagnosis of triple-negative breast cancer-with such determination and grace.

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who discussed his position at the 32nd Annual Miami Breast Cancer Conference on Sunday.

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, discusses how nurses can help their patients.

Pain in patients with breast cancer who have had surgery or who have late-stage disease is common, and managing it effectively can be difficult.

Women with HR-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent- tamoxifen compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

Erin W. Hofstatter, MD, assistant professor of medicine (medical oncology), co-director, Genetic Counseling Program, Yale Cancer Center, discusses chemoprevention to reduce one's risk of developing breast cancer.

This portion will discuss the conceptualization of health in rural areas and barriers to accessing healthcare.

The big difference in progression-free survival seen in pivotal trial data propelled palbociclib to its accelerated FDA approval for the treatment of metastatic breast cancer, bringing with it the potential for the drug to quickly become adapted as the new standard of care, Brian Wojciechowski, MD, said.

Jack Cuzick, PhD, a professor of epidemiology at Wolfson Institute of Preventive Medicine, discusses how to determine if a woman is at high risk of developing breast cancer and which of these women should consider taking tamoxifen as a preventative measure.

Women diagnosed with early-stage breast disease have a variety of decisions to make regarding their treatment options. For example, some women may be eligible for breast-conserving surgery, which typically includes a lumpectomy followed by radiation.

Jean Weigert, MD, head of breast imaging for the Hospital of Central Connecticut, discusses a study conducted in Connecticut to see if the addition of screening breast ultrasound in women with mammographically normal but dense breasts has increased breast cancer detection.